Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06398873
Status:
RECRUITING
Last Update Posted:
2024-06-12
First Post:
2024-04-25
Brief Title:
Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP
Sponsor:
Medical University of Vienna
Organization:
Medical University of Vienna
Study Overview
Official Title:
Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With Chronic Rhinosinusitis With Nasal Polyps CRSwNP - an Exploratory Pilot Study
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EpiBar
Brief Summary:
The investigators aim to investigate two major so far unresolved topics in CRSwNP research 1 Thorough functional and molecular characterisation of barrier function in patients suffering from CRSsNP and CRSwNP and 2 effect of dupilumab treatment on barrier function in polyp patients This will be achieved in patient-derived samples by employing measurement of barrier function in primary cell cultures in combination with a mass cytometry based imaging approach transcriptomic analysis as well as cytokine and microbiome data of individual patients
Detailed Description:
Primary objective 1 Characterization of differences in barrier function of the nasal epithelium in patients suffering from CRSsNP CRSwNP with and without asthma or N-ERD in absence of therapy with monoclonal antibodies T Primary objective 2 Effect of dupilumab treatment on barrier function of the nasal epithelium in patients suffering from CRSwNP with and without asthma or N-ERD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None